Effects of Tianma Gouteng Yin combined with butylphthalide on symptom improvement and vascular elasticity in patients with acute cerebral infarction

doi:10.11958/20241191

Abstract

Abstract:

Objective To explore the effect of Tianma Gouteng Yin combined with butylphthalein (NBP) on symptom improvement and vascular elasticity in patients with acute cerebral infarction (ACI). Methods Eighty-two ACI patients admitted to Lu'an Hospital of Traditional Chinese Medicine were included in this study, and they were randomly separated into the single group and the combination group, with 41 cases in each group. The single group was given intravenous infusion of NBP sodium chloride injection, and the combination group was given treatment with Tianma Gouteng Yin on the basis of the single group. Cerebrovascular reserve function, endothelial function, neurological function, independent living ability, hemodynamic indicators, vascular elasticity, clinical efficacy and incidence of adverse reactions were compared between the two groups of patients at 1 day after admission (T₀) and 14 days after treatment (T₁). Results There were no significant differences in cerebrovascular reserve function, endothelial function, National Institutes of Health Stroke Scale (NIHSS) scores, independent living ability scores, hemodynamic indicators and vascular elasticity indicators at T₀ between the two groups (P>0.05). At T₁, levels of cerebrovascular reactivity (CVR), nitric oxide (NO), nitric oxide synthase (NOS), large artery elasticity index (C₁) and small artery elasticity index (C₂) were significantly increased in both groups, and levels were higher in the combined group than those of the single group (P<0.05). At T₁ moment, levels of ET-1, vascular endothelial growth factor (VEGF), NIHSS score, MRS score, red blood cell count, whole blood viscosity, platelet adhesion rate and arterial pressure were reduced in both groups, and levels were lower in the combined group than those of the single group (P<0.05). The total effective rate was higher in the combination group (80.5%) than that of the single group (46.3%). The overall incidence of adverse reactions was lower in the combined group than that in the single group (P<0.05). Conclusion Tianma Gouteng Yin combined with NBP can effectively improve the cerebral vascular reserve function, endothelial function and neurological damage in ACI patients, increase vascular elasticity and improve hemodynamic levels.

Key words: brain infarction, Tian Ma Gou Teng Yin, butylphthalide, symptom improvement, vascular elasticity

CLC Number:

R743.33

Figures/Tables 8

References 20

[1]	MENDELSON S J, PRABHAKARAN S. Diagnosis and management of transient ischemic attack and acute ischemic stroke:a review[J]. JAMA, 2021, 325(11):1088-1098. doi:10.1001/jama.2020.26867.
[2]	ZHAO Y, ZHANG X, CHEN X, et al. Neuronal injuries in cerebral infarction and ischemic stroke:from mechanisms to treatment(Review)[J]. Int J Mol Med, 2022, 49(2):15. doi:10.3892/ijmm.2021.5070.
[3]	LI T, YUAN D, YUAN J. Antithrombotic drugs-pharmacology and perspectives[J]. Adv Exp Med Biol, 2020, 1177:101-131. doi:10.1007/978-981-15-2517-9_4.
[4]	库成心, 邓丽影, 谢亮. 缺血性卒中继发日间过度思睡研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8):683-686.
	KU C X, DENG L Y, XIE L. Progress on excessive daytime sleepiness secondary to ischemic stroke[J]. Chin J Contemp Neurol Neurosurg, 2023, 23(8):683-686. doi:10.3969/j.issn.1672-6731.2023.08.006.
[5]	TANG X, LU J, CHEN H, et al. Underlying mechanism and active ingredients of Tianma Gouteng acting on cerebral infarction as determined via network pharmacology analysis combined with experimental validation[J]. Front Pharmacol, 2021, 12:760503. doi:10.3389/fphar.2021.760503.
[6]	刘鸣, 蒲传强. 中国急性缺血性脑卒中诊治指南2014[J]. 中华神经科杂志, 2015, 48(4):246-257.
	LIU M, PU C Q. Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2014[J]. Chinese Journal of Neurology, 2015, 48(4):246-257.
[7]	PREEDY V R, WATSON R R. Handbook of Disease Burdens & Quality of Life Measures[M]. New York: Springer, 2010:4263,4270.
[8]	陈清棠. 脑卒中患者临床神经功能缺损程度评分标准(1995)[J]. 中华神经科杂志, 1996, 29(6):381-383.
	CHEN Q T. Scoring criteria for clinical neurological deficits in stroke patients(1995)[J]. Chinese Journal of Neurology, 1996, 29(6):381-383.
[9]	BENNETT C, MOHAMMED F, ÁLVAREZ-CIARA A, et al. Neuroinflammation,oxidative stress,and blood-brain barrier(BBB) disruption in acute Utah electrode array implants and the effect of deferoxamine as an iron chelator on acute foreign body response[J]. Biomaterials, 2019, 188:144-159. doi:10.1016/j.biomaterials.2018.09.040.
[10]	KOÇKAR İ N, KOYUNCUOĞLU H R. Pathophysiology of parenchymal injury in ischemic stroke[J]. Academic Journal of Neurology and Neurosurgery, 2024, 1(1):5-10.
[11]	ZHANG H, WU H, QI X, et al. Effect of butylphthalide combined with idebenone on vascular dementia:a retrospective observational analysis[J]. Medicine(Baltimore), 2024, 103(9):e37495. doi:10.1097/MD.0000000000037495.
[12]	张彦彦, 李晶洁, 龙芸鸾, 等. 天麻钩藤饮防治神经系统疾病的研究进展[J]. 中成药, 2022, 44(9):2901-2905.
	ZHANG Y Y, LI J J, LONG Y L, et al. Research progress on the prevention and treatment of neurological diseases with Tianma Gouteng drink[J]. Traditional Chinese Patent Medicines and Simple Preparations, 2022, 4(9):2901-2905. doi:10.3969/j.issn.1001-1528.2022.09.027.
[13]	BONNIN P, CHARRIAUT-MARLANGUE C, PANSIOT J, et al. Cerebral vasodilator property of poly(ADP-ribose) polymerase inhibitor(PJ34) in the neonatal and adult mouse is mediated by the nitric oxide pathway[J]. Int J Mol Sci, 2020, 21(18):6569. doi:10.3390/ijms21186569.
[14]	JAIME GARCIA D, CHAGNOT A, WARDLAW J M, et al. A scoping review on biomarkers of endothelial dysfunction in small vessel disease:molecular insights from human studies[J]. Int J Mol Sci, 2023, 24(17):13114. doi:10.3390/ijms241713114.
[15]	ZHOU X, SHAO T, XIE X, et al. Tongqiao Huoxue Decoction for the treatment of acute ischemic stroke:a systematic review and meta-analysis[J]. J Ethnopharmacol, 2022, 283:114693. doi:10.1016/j.jep.2021.114693.
[16]	张彦彦, 李晶洁, 龙芸鸾, 等. 天麻钩藤饮在防治心脑血管疾病中的应用研究评述[J]. 中国中医基础医学杂志, 2024, 30(1):152-157.
	ZHANG Y Y, LI J J, LONG Y L, et al. Review on the application of Tianma Gouteng Drink in the prevention and treatment of cardiovascular and cerebrovascular diseases[J]. Chinese Journal of Basic Traditional Chinese Medicine, 2024, 30(1):152-157.
[17]	崔海彬, 张倩. 天麻素对脑缺血再灌注大鼠大脑皮质的影响及可能机制[J]. 解剖科学进展, 2021, 27(3):277-279,283.
	CUI H B, ZHANG Q. The effect and possible mechanism of gastrodin on the cerebral cortex of rats with cerebral ischemia-reperfusion injury[J]. Advances in Anatomy Science, 2021, 27(3):277-279,283. doi:10.16695/j.cnki.1006-2947.2021.03.006.
[18]	ROBLES F B, PANERAI R B, KATSOGRIDAKIS E, et al. Superior fitting of arterial resistance and compliance parameters with genetic algorithms in models of dynamic cerebral autoregulation[J]. IEEE Trans Biomed Eng, 2022, 69(1):503-512. doi:10.1109/TBME.2021.3100288.
[19]	CHENG Q, TONG F, SHEN Y, et al. Achyranthes bidentata polypeptide k improves long-term neurological outcomes through reducing downstream microvascular thrombosis in experimental ischemic stroke[J]. Brain Res, 2019, 1706:166-176. doi:10.1016/j.brainres.2018.11.010.
[20]	GAO J W, YAO Y C, WANG B, et al. Exploring the molecular mechanisms of eucommia ulmoides extract intreating atherosclerosis based on network pharmacology and molecular docking technology[J]. MEDS Clinical Medicine, 2023, 4(3):1-11. doi:10.23977/medsc.2023.040301.

组别	年龄/岁	脑梗死类型				病程/h	体质量指数/（kg/m²）	基础疾病
组别	年龄/岁	基底节	腔隙性	多发性	其他	病程/h	体质量指数/（kg/m²）	高血压	糖尿病	其他^△
单一组	70.10±5.63	16（39.0）	10（24.4）	7（17.1）	8（19.5）	18.85±2.12	22.51±2.3	20（48.8）	11（26.8）	10（24.4）
联合组	68.95±6.35	18（43.9）	9（21.9）	8（19.5）	6（14.6）	19.02±2.13	22.06±2.3	19（46.3）	10（24.4）	12（29.3）
t或χ²	0.868	0.523				0.370	0.889	0.255

组别	年龄/岁	脑梗死类型				病程/h	体质量指数/（kg/m²）	基础疾病
组别	年龄/岁	基底节	腔隙性	多发性	其他	病程/h	体质量指数/（kg/m²）	高血压	糖尿病	其他^△
单一组	70.10±5.63	16（39.0）	10（24.4）	7（17.1）	8（19.5）	18.85±2.12	22.51±2.3	20（48.8）	11（26.8）	10（24.4）
联合组	68.95±6.35	18（43.9）	9（21.9）	8（19.5）	6（14.6）	19.02±2.13	22.06±2.3	19（46.3）	10（24.4）	12（29.3）
t或χ²	0.868	0.523				0.370	0.889	0.255

组别	CVR/%
组别	T₀	T₁	t
单一组	20.53±3.32	39.57±5.30	20.207^＊＊
联合组	20.50±3.29	45.03±5.18	23.922^＊＊
t	0.054	4.730^＊＊

组别	CVR/%
组别	T₀	T₁	t
单一组	20.53±3.32	39.57±5.30	20.207^＊＊
联合组	20.50±3.29	45.03±5.18	23.922^＊＊
t	0.054	4.730^＊＊

组别	NIHSS			MRS
组别	T₀	T₁	t	T₀	T₁	t
单一组	15.54±2.13	7.02±1.23	21.535^＊＊	3.78±0.57	2.56±0.50	9.872^＊＊
联合组	14.71±2.00	5.20±0.98	32.299^＊＊	3.56±0.50	1.56±0.50	17.268^＊＊
t	1.814	7.430^＊＊		1.849	9.012^＊＊